Cargando…

PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors

Thyroid carcinomas are the most prevalent endocrine cancers. The BRAF(V600E) mutation is found in 40% of the papillary type and 25% of the anaplastic type. BRAF(V600E) inhibitors have shown great success in melanoma but, they have been, to date, less successful in thyroid cancer. About 50% of anapla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roelli, Matthias A., Ruffieux-Daidié, Dorothée, Stooss, Amandine, ElMokh, Oussama, Phillips, Wayne A., Dettmer, Matthias S., Charles, Roch-Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732722/ https://www.ncbi.nlm.nih.gov/pubmed/29262556 http://dx.doi.org/10.18632/oncotarget.21732

Ejemplares similares

Identification of effective natural PIK3CA H1047R inhibitors by computational study
por: Liu, Naimeng, et al.
Publicado: (2021)

Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
por: Gkeka, Paraskevi, et al.
Publicado: (2014)

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
por: Cufí, Sílvia, et al.
Publicado: (2013)

Generation of a tree shrew breast cancer model using lentivirus expressing PIK3CA-H1047R
por: Zeng, Li, et al.
Publicado: (2023)

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
por: Yuan, W, et al.
Publicado: (2013)

Recurrent PIK3CA H1047R-Mutated Congenital Infiltrative Facial Lipomatosis: A Case Report and Review of Literature
por: Oh, Kei Shing, et al.
Publicado: (2023)

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R
por: Meyer, D S, et al.
Publicado: (2013)

The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways
por: Candido, Saverio, et al.
Publicado: (2022)

Highly sensitive detection of the PIK3CA(H1047R) mutation in colorectal cancer using a novel PCR-RFLP method
por: Li, Wan-Ming, et al.
Publicado: (2016)

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation
por: Bleckmann, Annalen, et al.
Publicado: (2020)

Combined MEK and Pi3′-kinase inhibition reveals synergy in targeting thyroid cancer in vitro and in vivo
por: ElMokh, Oussama, et al.
Publicado: (2017)

A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation
por: Kalofonou, Melpomeni, et al.
Publicado: (2020)

NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CA(H1047R) homozygosity in pluripotent stem cells
por: Madsen, Ralitsa R., et al.
Publicado: (2021)

S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis
por: Yuan, Wenlin, et al.
Publicado: (2019)

Physiological Levels of Pik3ca (H1047R) Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors
por: Tikoo, Anjali, et al.
Publicado: (2012)

Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers
por: Lee, Kang-Hoon, et al.
Publicado: (2019)

PIK3CA(H1047R) and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
por: Cheng, Hailing, et al.
Publicado: (2015)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

DMBA induced mouse mammary tumors display high incidence of activating Pik3ca(H1047) and loss of function Pten mutations
por: Abba, Martín C., et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers
por: Engelman, Jeffrey A., et al.
Publicado: (2008)

Introduction and expression of PIK3CA(E545K) in a papillary thyroid cancer BRAF(V600E) cell line leads to a dedifferentiated aggressive phenotype
por: Pinto, Nicole, et al.
Publicado: (2022)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

The Genomic Environment of BRAF Mutated and BRAF/PIK3CA Double Mutated Colorectal Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

High frequency of BRAF V600E mutations in ameloblastoma
por: Kurppa, Kari J, et al.
Publicado: (2014)

BRAF V600E-Negative Hairy Cell Leukaemia
por: Langabeer, Stephen E., et al.
Publicado: (2013)

Intrathoracic synovial sarcoma with BRAF V600E mutation
por: Russo, Ida, et al.
Publicado: (2023)

The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
por: Eklöf, V, et al.
Publicado: (2013)

BRAF V600K vs. BRAF V600E: a comparison of clinical and dermoscopic characteristics and response to immunotherapies and targeted therapies
por: Zengarini, Corrado, et al.
Publicado: (2022)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Clinical neuropathology practice news 2-2012: BRAF V600E testing
por: Capper, David, et al.
Publicado: (2012)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

Oncogenic BRAF(V600E) Induces Clastogenesis and UVB Hypersensitivity
por: Simpson, Dennis A., et al.
Publicado: (2015)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
por: Park, Charny, et al.
Publicado: (2015)

Adult classical glioblastoma with a BRAF V600E mutation
por: Takahashi, Yoshinobu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_577d9qntju8arr2g40oiees2qg